Filtered By:
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 303 results found since Jan 2013.
A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination
J Korean Med Sci. 2022 Apr 4;37(13):e104. doi: 10.3346/jkms.2022.37.e104.ABSTRACTVaccines have become the mainstay of management against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) in the absence of effective antiviral therapy. Various adverse effects of COVID-19 vaccination have been reported, including cardiovascular complications such as myocarditis or pericarditis. Herein, we describe clinical records of a 63-year woman with fulminant myocarditis following ChAdOx1 nCoV-19 vaccination that was salvaged by heart transplantation. She complained chest pain, na...
Source: J Korean Med Sci - April 5, 2022 Category: General Medicine Authors: Seok Hyun Kim Soo Yong Lee Ga Yun Kim Ji Soo Oh Jeongsu Kim Kook Jin Chun Min Ho Ju Chee-Hoon Lee Yeo-Jeong Song Joo-Young Na Source Type: research
Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Fever, Myalgias, and Weakness in a Patient with HIV
A 62-year-old Bolivian man residing in Spain since 2002, diagnosed with human immunodeficiency virus (HIV) infection in 2014 and with poor adherence to antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide), presented to the Emergency Department with 2-month history of asthenia, myalgias, and weakness. He complained of increased weakness and pain in his right arm, in addition to edema and distal paresthesia 10 days after he received the pneumococcal conjugate vaccine (Prevenar 13) in the same arm.
Source: The American Journal of Medicine - February 27, 2022 Category: General Medicine Authors: Marta Lobo Antu ña, Edwin Uriel Suárez M, Silvia Calpena Martínez, Fernando Lage Estebañez, Jose Fortes Alén, Miguel de Górgolas Hernández-Mora Tags: Diagnostic Dilemma Source Type: research
Fever, myalgias and weakness in a patient with HIV
A 62-year-old Bolivian man residing in Spain since 2002 diagnosed with HIV infection in 2014 and with poor adherence to antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide) presented to the emergency department with 2-month history of asthenia, myalgias, and weakness. He complained of increased weakness and pain in his right arm in addition to edema and distal paresthesia 10 days after he received the pneumococcal conjugate vaccine (PCV13/Prevnar) in the same arm. His most recent CD4+ T cell count was 174 cells/ml and he had a viral load of 114 copies/ml.
Source: The American Journal of Medicine - February 27, 2022 Category: General Medicine Authors: Marta Lobo Antu ña, Edwin Uriel Suárez Merchán, Silvia Calpena Martínez, Fernando Lage Estebañez, Jose Fortes Alén, Miguel de Górgolas Hernández-Mora Tags: Diagnostic Dilemma Source Type: research
COVID-19 Killed My Grandfather. But My Dad Was Too Busy Treating COVID-19 Patients to Grieve Him
In early February, I got the call I’d dreaded for months: my 82-year-old grandfather, Charlie Law, had died. I’d tried to prepare myself as best as I could; Grandpa had Parkinson’s disease and dementia, and he had been in physical and mental decline for about four years. Still, I hadn’t seen my grandparents in person for two of those years because of the pandemic.
Once the initial waves of shock and sadness had washed over me, I was surprised to find I was angry. Losing my grandfather was inevitable, but it felt as if the disease that finally took his life—COVID-19—was not. Although my g...
Source: TIME: Health - February 24, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)
CONCLUSIONS: V114 is well tolerated with a consistent safety profile and immune response across manufacturing lots.CLINICAL TRIALS REGISTRATION: NCT03950856 (www.clinicaltrials.gov); 2018-004266-33 (EudraCT).PMID:35039194 | DOI:10.1016/j.vaccine.2021.12.067
Source: Vaccine - January 18, 2022 Category: Allergy & Immunology Authors: Jakub K Simon Nina Breinholt Staerke Maria Hemming-Harlo Stacey Layle Ron Dagan Tulin Shekar Alison Pedley Patricia Jumes Gretchen Tamms Tina Sterling Luwy Musey Ulrike K Buchwald V114-020 PNEU-TRUE study group Source Type: research
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetectable min...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
